Reslizumab for uncontrolled eosinophilic asthma in patients who experienced a single exacerbation in the previous year: sub-analysis of two phase 3 trials Source: International Congress 2017 – Asthma management Year: 2017
Randomized trial of HFA-salbutamol versus CFC-salbutamol via MDI with spacer for acute wheezing exacerbations in children less than 2 years of age Source: Eur Respir J 2002; 20: Suppl. 38, 430s Year: 2002
A randomized, placebo-controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease(COPD) Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010
Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015
Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Patient-reported chronic cough severity over 52 weeks in two phase 3 trials of gefapixant Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021
Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients Source: Eur Respir J, 58 (6) 2101702; 10.1183/13993003.01702-2021 Year: 2021
Comparison of ciclesonide 160 μg/d with budesonide 400 μg/d in a randomised, double-blind study in children with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 711s Year: 2006
Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials Source: Eur Respir J 2001; 18: Suppl. 33, 331s Year: 2001
Efficacy of montelukast in patients aged 2 to 5 years with mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 377s Year: 2004
A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks Source: Eur Respir J 2002; 20: Suppl. 38, 406s Year: 2002
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016
Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021
Prednisolone for preschool children presenting with acute wheeze: A multicentre RCT. Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017
Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis Source: International Congress 2017 – Asthma management Year: 2017
Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial) Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013